Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Return on Equity (2022 - 2025)

Historic Return on Equity for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 4.36%.

  • bioAffinity Technologies' Return on Equity fell 17800.0% to 4.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.36%, marking a year-over-year decrease of 17800.0%. This contributed to the annual value of 2.42% for FY2024, which is 14300.0% down from last year.
  • bioAffinity Technologies' Return on Equity amounted to 4.36% in Q3 2025, which was down 17800.0% from 33.55% recorded in Q2 2025.
  • bioAffinity Technologies' Return on Equity's 5-year high stood at 33.55% during Q2 2025, with a 5-year trough of 4.82% in Q1 2025.
  • Its 4-year average for Return on Equity is 0.84%, with a median of 1.5% in 2023.
  • The largest annual percentage gain for bioAffinity Technologies' Return on Equity in the last 5 years was 355700bps (2025), contrasted with its biggest fall of -31600bps (2025).
  • Quarter analysis of 4 years shows bioAffinity Technologies' Return on Equity stood at 0.69% in 2022, then plummeted by -94bps to 1.34% in 2023, then tumbled by -136bps to 3.16% in 2024, then crashed by -38bps to 4.36% in 2025.
  • Its Return on Equity stands at 4.36% for Q3 2025, versus 33.55% for Q2 2025 and 4.82% for Q1 2025.